Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE illection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are req

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

	OFFE 25 LAD				
Attorney Docket No.	9577-25 LAB				
First Inventor	Amina Odidi				
Title	Extended Release Pharmaceuticals				
Express Mail Label No).				

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	Assistant Commissioner for Patents ADDRESS TO: Box Patent Application Washington, D.C. 20231		
Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)		
2. Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)		
3 J Specification Total Pages 14]	a. Computer Readable Form (CRF)		
(preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D	b. Specification Sequence Listing on: i.		
Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention	ii paper c Statements verifying identity of above copies		
- Brief Summary of the Invention	ACCOMPANYING APPLICATION PARTS		
 Brief Description of the Drawings (if filed) Detailed Description 	9 Assignment Papers (cover sheet & document(s))		
- Claim(s) - Abstract of the Disclosure	10 37 CFR 3 73(b) Statement (when there is an assignee) Power of Attorney		
	11 English Translation Document (if applicable)		
4 Drawing(s) (35 U.S.C. 113) [Total]	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations		
5. Oath or Declaration [Total Pages 3]	13. Preliminary Amendment		
a. Newly executed (original or copy)	Return Receipt Postcard (MPEP 503)		
Copy from a prior application (37 CFR 1.63(d) b. (for continuation/divisional with Box 18 completed)	(Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed)		
DELETION OF INVENTOR(S)	Request and Certification under 35 U.S.C. 122		
i. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.			
1 63(d)(2) and 1 33(b). 6. Application Data Sheet. See 37 CFR 1.76	17. Other: NONPUBLICATION REQUEST UNDER 35 U.S.C 122(b)(2)(B)(i)		
18. If a CONTINUING APPLICATION, check appropriate box, and	d supply the requisite information below and in a preliminary amendment,		
or in an Application Data Sheet under 37 CFR 1.76 Continuation Divisional Continuation-in-p	eart (CIP) of prior application No.:/		
Prior application information: Examiner	Group / Art Unit		
The entire dicalor	sure of the prior application, from which an oath or declaration is supplied anying continuation or divisional application and is hereby incorporated by has been inadvertently omitted from the submitted application parts.		
19. CORRESPO	ONDENCE ADDRESS		
Customer Number or Bar Code Lat	or Correspondence address below		
747	23		
Name PATENT TRADE	EMARK OFFICE		
Address			
City State	Zip Code		
Country Telephone	Fax		
Name (Print/Type) Lola A. Barttoszewicz	Registration No. (Attorney/Agent) 43394		
Signature V Day () Als () Day () A	Date May 1, 2001		

Burden Hour Statement This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case Any comments on the amount of time you are reduired to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

itals

Sianature

PTO/SB/17 (11-00)
Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office U.S DEPARTMENT OF COMMERCE
r the Paperwork Reduction Act of 1995, no persons are required to r espond to a collection of information unless it displays a valid OMB control number Unde

FEE TRANSM		Complete if Known				
	14	Application Number				
for FY 200	<i>/</i> 1	Filing Date				
		First Named Inventor	Amina Odidi			
Patent fees are subject to annual re	evision	Examiner Name				
		Group Art Unit				
TOTAL AMOUNT OF PAYMENT	\$503.00	Attorney Docket No.	9577-25 LAB			

METHOD OF PAYMENT				FE	E CALCULATION (continued)	
The Commissioner is hereby authorized to charge	3. AI				ES	
1. Lindicated fees and credit any overpayments to Deposit	Large E Fee	Fee	Fee	Fee	Fee Description	Fee Paid
Account Number 192253	Code 105	(\$) 130	Code 205	(\$) 65	Surcharge - late filing fee or oath	
Deposit Account Sim & McRurnov	127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
Name Sim & Fiebuliley	139	130	139	130	Non - English specification	
Charge Any Additional Fee Required Under 37 CFR §§ 1 16 and 1 17	147	2,520	147	2,520	For filing a request for ex parte reexamination	
Applicant claims small entity status See 37 CFR § 1 27	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
2. X Payment Enclosed:	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
Check Credit card Money Other	115	110	215	55	Extension for reply within first month	
FEE CALCULATION	116	390	216	195	Extension for reply within second month	
1. BASIC FILING FEE	117	890	217	445	Extension for reply within third month	
Large Entity Small Entity	118	1,390	218		Extension for reply within fourth month	
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	128	1,890	228		Extension for reply within fifth month	
101 710 201 355 Utility filing fee 355.00	119	310	219	155	Notice of Appeal	
106 320 206 160 Design filing fee	120	310	220	155	Filing a brief in support of an appeal	
107 490 207 245 Plant filing fee	121	270	221		Request for oral hearing	
108 710 208 355 Reissue filing fee	138	1,510			Petition to institute a public use proceeding	
114 150 214 75 Provisional filing fee	140	110	240	55		
SUBTOTAL (1) \$355.00		1,240	241		Petition to revive - unintentional	
2. EXTRA CLAIM FEES		1,240	242	620		
Fee from	143			220	•	
Extra Claims below Fee Paid Total Claims 32 -20** = 12 X 9.00 = 108.00	144	600			Plant issue fee	
Independent $\frac{32}{4} - 3^{**} = \frac{1}{1} \times \frac{40.00}{40.00} = \frac{40.00}{1}$	122				Petitions to the Commissioner Processing fee under 37 CFR § 1 17(q)	
Claims Multiple Dependent =	123					
Large Entity Small Entity	126	180	126	180	Statement	
Fee Fee Fee Fee Description Code (\$) Code (\$)	581	40	581	40	Recording each patent assignment per property (times number of properties)	
103 18 203 9 Claims in excess of 20	146	710	246	355	Filing a submission after final rejection (37 CFR § 1 129(a))	
102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be examined (37 CFR § 1 129(b))	
109 80 209 40 ** Reissue independent claims	179	710	279	355	Request for Continued Examination (RCE)	
over original patent	169			900	Request for expedited examination	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	Oth	ner fee	(specify	/)	of a design application	
SUBTOTAL (2) \$148.00			-			
**or number previously paid, if greater, For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3)						
SUBMITTED BY Complete (if applicable)						
Name (Print/Type) Lola A. Bartoszewicz		Regist	ration N	lo	43394 Telephone 416 595 1155	5 ext. 200

WARNING Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Date

May 1, 2001

REQUEST AND CERTIFICATION
UNDER
35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor		Amina Odidi
Title	Extended Rel	ease Pharmaceuticals
Atty Do	cket Number	9577-25

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

May 1, 2001

Date

Signature

Lola A. Bartoszewicz

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit:

Examiner:

Inventors:

Isa Odidi and Amina Odidi

Serial No.:

Filed:

Title:

Extended Release Pharmaceuticals

April 30, 2001

BY OVERNIGHT COURIER

Commissioner for Patents and Trademarks Washington, D.C. 20231

Sir:

Attached herewith are the following:

- 1. Utility Patent Application Transmittal Sheet;
- 2. Fee Transmittal for FY 2001;
- 3. Request and Certification under 35 USC 122 (b)(2)(B)(i);
- 4. Initial Information Data Sheet;
- 5. Copy of executed Declaration and Power of Attorney;
- 6. Specification, claims and abstract; and
- 7. Cheque in the amount of US\$503.00.

Please sign and date the enclosed postcard in acknowledgement of the above documents.

Respectfully submitted,

SIM & MCBURNEY

Dr. Lola A. Bartoszewicz, Ph.D.

Registration No. 43/394

330 University Avenue, 6th Floor Toronto, Ontario M5G 1R7 (416) 595 1155

LAB/ca Encls